-
Study aim
-
Evaluating the effect of barley-based product on controlling the symptoms of hospitalized patients with COVID-19 and the recovery process
-
Design
-
Randomized parallel clinical trial with control group, phase 3, design of 60 patients, random allocation software was used for randomization.
-
Settings and conduct
-
Sixty hospitalized patients with a positive nasopharyngeal PCR test or a suspected chest CT scan are randomly assigned to one of the two groups of barley-based remedy or control. Patients in the intervention group, in addition to the usual treatments, receive a glass of barley-based remedy twice a day for 5 days. The consequences of the study, including laboratory results, clinical signs, and chest x-rays, are measured daily for 5 days
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Confirming informed consent and Positive Nasopharyngeal RT-PCR Test or CT Chest
Exclusion criteria: Intubated or hospitalized patient in ICU, pregnant and lactating women, diabetic patients, patients treated with corticosteroids or immunosuppressive drugs, patients undergoing dialysis, use of herbal medicines or other traditional and complementary medicine methods
-
Intervention groups
-
Intervention group: Receiving conventional medicine and receiving barley-based remedy for 5 days twice a day and one glass each time
Control group: Receiving common medicine drugs
-
Main outcome variables
-
Laboratory results (number of lymphocytes, CRP), clinical symptoms (fever, cough, myalgia, shortness of breath, chills) Chest x-ray